ACAT2 as a novel therapeutic target to treat fatty liver disease

被引：5
|
作者：
Romeo, Stefano [1 ,2 ,3 ]
机构：
[1] Univ Gothenburg, Sahlgrenska Acad, Wallenberg Lab, Dept Mol & Clin Med,Inst Med, Bruna Straket 16, S-41345 Gothenburg, Vastra Gotaland, Sweden
[2] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden
[3] Magna Graecia Univ Catanzaro, Dept Med & Surg Sci, Clin Nutr Unit, Catanzaro, Italy
来源：
JOURNAL OF INTERNAL MEDICINE | 2022年 / 292卷 / 02期
关键词：
NASH; Fatty liver; Soat2; MAFLD; NAFLD;
D O I：
10.1111/joim.13460
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：175 / 176
页数：2
相关论文
共 50 条
  • [31] Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver
    Yamagishi, S
    Nakamura, K
    Matsui, T
    Sato, T
    Takeuchi, M
    MEDICAL HYPOTHESES, 2006, 66 (04) : 844 - 846
  • [32] Control of ACAT2 Liver Expression by HNF4α Lesson From MODY1 Patients
    Pramfalk, C.
    Karlsson, E.
    Groop, L.
    Rudel, L. L.
    Angelin, B.
    Eriksson, M.
    Parini, P.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2009, 29 (08) : 1235 - 1241
  • [33] The immune response as a therapeutic target in non-alcoholic fatty liver disease
    Ortiz-Lopez, Nicolas
    Fuenzalida, Catalina
    Soledad Dufeu, Maria
    Pinto-Leon, Araceli
    Escobar, Alejandro
    Poniachik, Jaime
    Pablo Roblero, Juan
    Valenzuela-Perez, Lucia
    Beltran, Caroll J.
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [34] Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease
    Pelusi, Serena
    Valenti, Luca
    LIVER INTERNATIONAL, 2019, 39 (02) : 250 - 256
  • [35] Serum uric acid: a new therapeutic target for nonalcoholic fatty liver disease
    Sun, Dan-Qin
    Wu, Sheng-Jie
    Liu, Wen-Yue
    Lu, Qian-Di
    Zhu, Gui-Qi
    Shi, Ke-Qing
    Braddock, Martin
    Song, Dan
    Zheng, Ming-Hua
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2016, 20 (03) : 375 - 387
  • [36] PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
    Cherubini, Alessandro
    Casirati, Elia
    Tomasi, Melissa
    Valenti, Luca
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2021, 25 (12) : 1033 - 1043
  • [37] Autophagy Dysregulation in Metabolic Associated Fatty Liver Disease: A New Therapeutic Target
    Chen, Chun-Liang
    Lin, Yu-Cheng
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (17)
  • [38] Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease
    Lefere, Sander
    Van de Velde, Frederique
    Hoorens, Anne
    Raevens, Sarah
    Van Campenhout, Sanne
    Vandierendonck, Astrid
    Neyt, Sara
    Vandeghinste, Bert
    Vanhove, Christian
    Debbaut, Charlotte
    Verhelst, Xavier
    Van Dorpe, Jo
    Van Steenkiste, Christophe
    Casteleyn, Christophe
    Lapauw, Bruno
    Van Vlierberghe, Hans
    Geerts, Anja
    Devisscher, Lindsey
    HEPATOLOGY, 2019, 69 (03) : 1087 - 1104
  • [39] How to treat the nonalcoholic fatty liver disease?
    Cadranel, Jean-Francois
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2009, 13 (06): : 234 - 238
  • [40] Dietary fatty acid-specific hepatic cholesterol ester accumulation is not due to regulation of ACAT2 gene expression
    Rudel, LL
    Davis, MA
    Shah, R
    Wallace, JM
    CIRCULATION, 2001, 104 (17) : 212 - 212
12345